- Home
- LYFT vs GH Comparison
LYFT vs GH Comparison
Compare LYFT & GH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LYFT
- GH
- Stock Information
- Founded
- LYFT 2007
- GH 2011
- Country
- LYFT United States
- GH United States
- Employees
- LYFT N/A
- GH N/A
- Industry
- LYFT Business Services
- GH Medical Specialities
- Sector
- LYFT Consumer Discretionary
- GH Health Care
- Exchange
- LYFT Nasdaq
- GH Nasdaq
- Market Cap
- LYFT 4.0B
- GH 3.0B
- IPO Year
- LYFT 2019
- GH 2018
- Fundamental
- Price
- LYFT $12.25
- GH $25.20
- Analyst Decision
- LYFT Buy
- GH Strong Buy
- Analyst Count
- LYFT 34
- GH 17
- Target Price
- LYFT $15.93
- GH $39.31
- AVG Volume (30 Days)
- LYFT 11.1M
- GH 2.5M
- Earning Date
- LYFT 11-06-2024
- GH 11-04-2024
- Dividend Yield
- LYFT N/A
- GH N/A
- EPS Growth
- LYFT N/A
- GH N/A
- EPS
- LYFT N/A
- GH N/A
- Revenue
- LYFT $5,095,182,000.00
- GH $643,810,000.00
- Revenue This Year
- LYFT $29.78
- GH $27.01
- Revenue Next Year
- LYFT $13.26
- GH $18.30
- P/E Ratio
- LYFT N/A
- GH N/A
- Revenue Growth
- LYFT 19.88
- GH 26.20
- 52 Week Low
- LYFT $8.85
- GH $15.81
- 52 Week High
- LYFT $20.82
- GH $37.04
- Technical
- Relative Strength Index (RSI)
- LYFT 58.78
- GH 43.13
- Support Level
- LYFT $11.04
- GH $23.07
- Resistance Level
- LYFT $12.07
- GH $27.13
- Average True Range (ATR)
- LYFT 0.55
- GH 1.30
- MACD
- LYFT 0.11
- GH 0.21
- Stochastic Oscillator
- LYFT 96.45
- GH 52.34
About LYFT Lyft Inc.
Lyft is the second-largest ride-sharing service provider in the US and Canada, connecting riders and drivers over the Lyft app. Incorporated in 2013, Lyft offers a variety of rides via private vehicles, including traditional private rides, shared rides, and luxury ones. Besides ride-share, Lyft also has entered the bike- and scooter-share market to bring multimodal transportation options to users.
About GH Guardant Health Inc.
Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2022, the company launched a lab-developed test version of Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.